BergenBio Fundamentale Forhold (BGBIO)

[TekBot]

BerGenBio Third Quarter Results 2024

Bergen, Norway, November 13, 2024 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharma-ceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, today announced financial results for the quarter
…

Vis børsmeldingen

and half year ended September 30, 2024, and provided a business update.

Highlights, including post period:

BGBC016 1L NSCLC STK11m Study

· Ph1b enrollment completed; acceptable safety and pharmacokinetics announced
in September 2024
· The Ph2a portion of the study continues to accrue patients both in the US
and in Europe

1L STK11m NSCLC: a Widely Recognized Risk Factor

· New published data from MD Anderson continues to support the need for
improved therapies in this patient population which is poorly served today

Tilvestamab

· After extensive out-reach, the Company has decided to discontinue all
tilvestamab activities including out-licensing activities

Martin Olin, Chief Executive Officer of BerGenBio stated: “BerGenBio continues
to progress its focused strategy to develop its lead AXL inhibitor bemcentinib
in first-line NSCLC patients with mutations in the STK11 gene which, we believe,
represent a significant commercial opportunity. The on-going BGBC016 study in
this population continues to progress and recently announced Ph1b data supports
the safety and adequate pharmacokinetics of bemcentinib in combination with
current standard of care therapy. The Ph2a portion of the study continues to
accrue patients both in the US and in Europe. We expect to share a first Interim
Analysis in the first part of 2025.”

Third Quarter 2024 Financial Highlights

· The operating loss for the quarter was NOK 24.8 million (2023: NOK 27.9
million)
· Net cash flow was negative by NOK 27.7 million (2023: NOK 55.4 million)
· Cash and cash equivalents amounted to NOK 174.8 million by the end of
September 2024 (NOK 200.1 million by end of June 2024 and NOK 169.3 million by
end of September 2023).

Presentation and Financial Report

The Q3 2024 Financial report is attached to this stock exchange announcement and
the report and the Q3 2024 presentation are available at the Company’s website
Financial reports - BerGenBio.

Webcast details

BerGenBio’s senior management team will provide a business update today at 10:00
am CET. The presentation will webcast live. To participate in the webcast,
please use the following link:

https://channel.royalcast.com/landingpage/hegnarmedia/20241113_3/ (https://eur03.
safelinks.protection.outlook.com/?url=https%3A%2F%2Fchannel.royalcast.com%2Flandi
ngpage%2Fhegnarmedia%2F20241113_3%2F&data=05%7C02%7Crune.skeie%40bergenbio.com%7C
edb3efe7d3544253b97808dcd95dbe8b%7C2b50b422ca6d42af9fc0741b248bb071%7C0%7C0%7C638
624243884009754%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBT
iI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=ChE2P8z0gkYJ%2FOCJVg3%2FQKZkmQetPdHN
qoI4ESGYj5c%3D&reserved=0)

A recording of the webcast will be available at www.bergenbio.com in the
Investors/Financial Reports section
(Financial reports - BerGenBio) shortly afterwards.

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in clinical development for STK11 mutated
NSCLC and preclinical development for severe respiratory infections.

BerGenBio is based in Bergen, Norway, with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and subject to the disclosure requirements pursuant to
section 5-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BerGenBio Appoints Olav Hellebø as CEO

Bergen, Norway, November 20, 2024 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, announced today the appointment of Olav Hellebø as
…

Vis børsmeldingen

CEO. Mr. Hellebø will assume the position on November 21, 2024.

Mr. Hellebø brings three decades of experience in the pharmaceutical and
biotechnology industries. Since 2023, he has served as board director in the
clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has
been a board director at the clinical stage biopharmaceutical company, Antev
Ltd, specializing in urology and oncology treatments. Prior to this, Mr.
Hellebø’s experience includes the role as CEO of ReNeuron Group PLC, a UK-based
clinical-stage company specializing in cell therapy for ophthalmic and neurology
-related diseases, and CEO at Clavis Pharma ASA, an oncology-focused biotech
company traded at the Oslo Stock Exchange. Mr Hellebø’s earlier career includes
leadership roles at UCB-Celltech, Novartis UK, and at Schering-Plough (now part
of Merck & Co.).

“BerGenBio is at the forefront of exploring highly selective AXL inhibition as a
therapeutic enhancement for the large number of patients with non-squamous non
-small cell lung cancer with mutations in the STK11 gene. I am thrilled to join
the company and look forward to collaborating with the board and team to advance
the candidate drug, bemcentinib, through the next stages of clinical development
and to take BerGenBio to the next phase”, said Olav Hellebø.

“Mr. Hellebø brings a wealth of experience as a leader in pharmaceutical and
biotechnology companies, with a strong track record of success. His extensive
expertise in leading biotech companies, raising capital, and securing
partnership deals makes him exceptionally well-suited to guide BerGenBio and to
execute on our focused strategy to study STK11m NSCLC patients in our on-going
Ph1b/2a BGBC016 trial”, said Chairman of the Board, Anders Tullgren.

Contacts

Anders Tullgren, Chair of the Board, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Jan Lilleby, Media Relations, BerGenBio ASA

jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visitwww.bergenbio.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[HJB]

Flott med ny leder. Gikk raskt det? Han virker til å være større ekspert på å hente penger enn ekspert på partnerskap.
Dette blir spennende….

[TekBot]

BerGenBio to Present Company Update at DNB Nordic Healthcare Conference

BERGEN, Norway, November 26, 2024- BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, announced that the Company will present at the DNB
…

Vis børsmeldingen

Nordic Healthcare Conference today in Oslo, Norway at 14:45-15:05 CET.

Chief Executive Officer Olav Hellebø will provide a business update including
progress of the ongoing BGBC016 clinical study in 1st line Non-Small Cell Lung
Cancer patients with STK11 mutations.

The presentation used at the conference will be available in the investor
section of the Company’s websitewww.bergenbio.com/investors/presentations at
time of the presentation.

-End-

Contacts

Olav Hellebø, CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit?www.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Financial calendar

Financial calendar for BerGenBio ASA

FINANCIAL YEAR 2024
…

Vis børsmeldingen

29.04.2025 - Annual Report
20.05.2025 - Annual General Meeting

26.02.2025 - Quarterly Report - Q4

FINANCIAL YEAR 2025

20.08.2025 - Half-yearly Report

21.05.2025 - Quarterly Report - Q1
19.11.2025 - Quarterly Report - Q3
19.02.2026 - Quarterly Report - Q4

This information is published pursuant to the requirements set out in the Continuing obligations.

Kilde

[TekBot]

BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial

Bergen, Norway, January 7, 2025 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing the novel, selective AXL kinase inhibitor
bemcentinib for lung cancer announced today that the first patient has been
…

Vis børsmeldingen

included in a clinical trial sponsored by the Mays Cancer Center at The
University of Texas Health Science Center at San Antonio (UT Health San
Antonio). The study is led by Josephine A. Taverna, MD, a thoracic oncologist at
the Mays Cancer Center and Associate Professor in the Division of Hematology and
Oncology at UT Health San Antonio.

“Dr. Taverna’s research has shown that AXL and JAK-STAT3 work in tandem to
transmit signals promoting tumor growth and metastasis in advanced lung cancer.
We are pleased to see this research advancing into clinical application and
believe this study aligns closely with BerGenBio’s strategic focus on addressing
the significant unmet needs of lung cancer patients, including first-line Non
-Small Cell Lung Cancer patients with mutations in the STK11 gene”, said Olav
Hellebø, Chief Executive Officer of BerGenBio.

The trial is designed to study BerGenBio’s bemcentinib in combination with
pacritinib, which is a JAK2 inhibitor indicated for treatment of the bone marrow
disorder myelofibrosis in patients with platelet counts below 50 x 109/L. It
works by blocking certain growth factors and cytokines. Pacritinib is marketed
in the United States as VONJO® and owned by Swedish Orphan Biovitrum AB (Sobi®)
(STO:SOBI), a specialized international biopharmaceutical company. Bemcentinib
is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor
tyrosine kinase, a promising therapeutic target for serious diseases.

The study will include patients with lung adenocarcinoma, the most common type
of lung cancer in the United States, accounting for approximately 40% of all
lung cancers.The study is funded by a grant from the National Cancer Institute
(NCI) of the National Institutes of Health (NIH).

Contacts

Olav Hellebø, CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

About the Trial (NCT 06516887)

The trial sponsored by the Mays Cancer Center at The University of Texas Health
Science Center at San Antonio is entitled “Study of Bemcentinib plus Pacritinib
in Patients with Advanced adenocarcinoma” is a Phase Ib/II, open-label, single
institution dose-escalation, safety, pharmacokinetics, pharmacodynamic and
efficacy study. It is anticipated that a total of 44 patients will be enrolled
in the trial. In the PhIb portion varying doses of bemcentinib and pacritinib
will be studied in combination to determine safety, tolerability and the maximum
tolerated dose. The Phase II portion of the trial will study the dose(s)
selected in Phase Ib and will assess the overall response rate and progression
free survival of treated patients.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer. The Company is focused on its proprietary
lead candidate, bemcentinib, a potentially first-in-class selective AXL
inhibitor in development for STK11 mutated NSCLC. BerGenBio is based in Bergen,
Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock
Exchange (ticker: BGBIO). For more information, visitwww.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BerGenBio ASA: Invitation to fourth quarter 2024 results webcast

Bergen, Norway, 18 February 2025- BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, will be announcing its results for the fourth quarter 2024
…

Vis børsmeldingen

on Wednesday 26 February 2025.

BerGenBio’s senior management team will provide a business update at 10:30 am
CET.

The presentation will webcast live. To participate in the webcast please use
this link:

https://channel.royalcast.com/landingpage/hegnarmedia/20250226_5/

The link to the live webcast and a recording of the webcast will be available at
www.bergenbio.com in the Investors/Financial Reports
section (Financial reports - BerGenBio).

The fourth quarter financial report and presentation will also be made available
on the Company’s website in the Investors/Financial Reports
section (Financial reports - BerGenBio) from 7:00am CET
the same day.

-End-

Contacts

Olav Hellebø, CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer. BerGenBio is based in Bergen, Norway with
a subsidiary in Oxford, UK.

The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BerGenBio - Disclosure of shareholding

Investinor Direkte AS (“Investinor”), has on 21 February 2025 sold 39,947 shares in BerGenBio ASA (“BerGenBio”). Following the transaction, Investinor now holds 1,915,433 shares in BerGenBio, corresponding to 4.90% of the share capital.

This disclosure is made pursuant to sections 4-2 and 4-3 of the Norwegian Securities Trading Act and is subject to the disclosure requirement pursuant to section 5-12 of the Norwegian Securities Trading Act.
…

Vis børsmeldingen

Kilde

[TekBot]

BerGenBio avslutter 1L STK11m NSCLC-studie og vil utforske strategiske alternativer

Bergen, Norge, 25. februar 2025 - BerGenBio ASA (OSE: BGBIO), et biofarmasøytisk
selskap i klinisk fase som utvikler den nye, selektive AXL-kinasehemmeren
bemcentinib for alvorlige sykdommer, kunngjorde i dag sin beslutning om å
…

Vis børsmeldingen

avslutte BGBC016-studien av bemcentinib i kombinasjon med standardbehandling hos
førstelinjepasienter (1L) med ikke-plateepitel ikke-småcellet lungekreft (NSCLC)
og en mutasjon i STK11-genet (STK11m).

“Det er selvfølgelig skuffende og uventet at vi nå avbryter studien. Jeg vil
uttrykke min dypeste takknemlighet til pasientene og helsepersonellet som deltok
i studien for denne vanskeligstilte pasientgruppen, samt til øvrige medarbeidere
som har jobbet utrettelig med dette prosjektet,” uttalte Olav Hellebø,
administrerende direktør i BerGenBio. “Vi mener at de foreløpige resultatene
ikke er sterke nok til at selskapet kan sikre ytterligere finansiering innenfor
den nåværende kontantbeholdningen for å fullføre studien slik den opprinnelig
var planlagt. Selskapet går nå inn i en ny fase hvor strategiske alternativer
vil bli utforsket, noe som kan inkludere et mulig salg, fusjon eller annen
strategisk transaksjon.”

Bakgrunn:

I 2024 kunngjorde selskapet at det hadde fullført rekrutteringen til Ph1b-delen
av studien, som viste akseptabel sikkerhet hos 1L NSCLC-pasienter uavhengig av
STK11-mutasjonsstatus, vurdert av en uavhengig kontrollkomité (DSMB). Foreløpige
indikasjoner på effekt ble observert hos de tre STK11m-behandlede pasientene i
Ph1b-delen, inkludert én pasient som opplevde en komplett respons og som
fortsatt har respons og som fremdeles er under behandling etter nesten to år.
Selskapet, i samråd med den uavhengige kontrollkomitéen, bestemte at de
innledende resultatene berettiget en videreføring av studien til Ph2a-delen.

I mars 2024 startet selskapet Ph2a-delen av studien, med mål om å rekruttere 40
evaluerbare 1L STK11m NSCLC-pasienter. Det primære endepunktet for Ph2a var
objektiv responsrate (ORR). For å vurdere muligheten for å sikre kortsiktig
finansiering, gjennomførte selskapet en foreløpig analyse av responsene hos de
10 effekt-evaluerbare STK11m-pasientene. Mens det var én respons i Ph1b, ble det
ikke observert ytterligere responser hos Ph2a-pasientene. Som følge av dette har
selskapet besluttet å avslutte BGBC016-studien.

Styret har nå igangsatt en prosess for å utforske strategiske alternativer. Som
en del av denne prosessen vil styret vurdere en rekke muligheter for selskapet,
inkludert, men ikke begrenset til, et mulig salg, fusjon eller annen strategisk
transaksjon. Det er ingen garanti for at denne prosessen vil resultere i en
transaksjon.

Kontakter

Olav Hellebø, CEO BerGenBio ASA
ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

Jan Lilleby, Investor Relations / Media Relations
jl@lillebyfrisch.no

Om BerGenBio ASA

BerGenBio er et biofarmasøytisk selskap i klinisk fase med fokus på å utvikle
transformative legemidler som retter seg mot AXL som en potensiell grunnstein i
behandlingen av aggressive sykdommer, inkludert kreft. BerGenBio har hovedkontor
i Bergen, Norge, med et datterselskap i Oxford, Storbritannia. Selskapet er
notert på Oslo Børs (ticker: BGBIO). For mer informasjon, besøk
www.bergenbio.com.

Fremtidsrettede uttalelser

Denne kunngjøringen kan inneholde fremtidsrettede uttalelser, som således ikke
er historiske fakta, men er basert på ulike forutsetninger, hvorav mange igjen
er basert på ytterligere forutsetninger. Disse forutsetningene er iboende
gjenstand for betydelige kjente og ukjente risikoer, usikkerheter og andre
viktige faktorer. Slike risikoer, usikkerheter, eventualiteter og andre viktige
faktorer kan medføre at faktiske hendelser avviker vesentlig fra forventningene
som uttrykkes eller antydes i denne kunngjøringen gjennom slike fremtidsrettede
uttalelser.

Denne informasjonen anses som innsideinformasjon i henhold til EUs
markedsmisbruksforordning og er underlagt offentliggjøringskravene i henhold til
verdipapirhandelloven § 5-12.

Kilde

[TekBot]

BerGenBio announces discontinuation of 1L STK11M NSCLC study and exploration of strategic alternatives

Bergen, Norway, February 25, 2025 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing the novel, selective AXL kinase inhibitor
bemcentinib for serious diseases today announced its decision to close its
…

Vis børsmeldingen

BGBC016 study of bemcentinib in combination with standard of care therapy in
first line (1L) non-squamous Non-Small Cell Lung Cancer (NSCLC) patients with a
mutation in the STK11 gene (STK11m).

“It is, of course, disappointing and unexpected that we are now discontinuing
the study. I would like to extend my gratitude to the patients and investigators
who participated in our study for this particularly difficult-to-treat patient
group, as well as to our team members who have worked tirelessly on this
effort”, stated Olav Hellebø, Chief Executive Officer of BerGenBio. “We do not
believe these preliminary results are strong enough for the company to obtain
additional funding within the current cash runway to complete the study as
originally designed. The company is now entering a new phase in which strategic
alternatives will be explored, which may include a potential sale, merger, or
other strategic transaction.”

Background:

In 2024, the company announced the completion of enrollment in the Ph1b portion
of the study which demonstrated acceptable safety in 1L NSCLC patients
regardless of STK11 mutational status, as evaluated by an independent Data
Safety Monitoring Board (DSMB). Early encouraging data were seen in three STK11m
patients, including one patient who experienced a complete response and who
remains in response and on treatment after nearly two years. The company, in
agreement with the independent DSMB, determined that these initial results
warranted the continuation of the study into the Ph2a portion.

In March 2024, the company initiated the Ph2a portion of the study designed to
recruit 40 evaluable 1L STK11m NSCLC patients. The primary endpoint for the Ph2a
was overall response rate (ORR). To determine the feasibility of obtaining near
-term funding, the company performed a preliminary analysis of the responses in
the 10 efficacy evaluable STK11m patients. While there was 1 response in the
Ph1b we did not observe additional responses in the Ph2a patients. Consequently,
the company has decided to discontinue the BGBC016 study.

The Board of Directors has now initiated an exploration of strategic
alternatives. As part of this process, the board will consider a range of
options for the company including, among other things, a potential sale, merger,
or other strategic transaction. There can be no assurance that this exploration
process will result in any transaction.

Contacts

Olav Hellebø, CEO BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Jan Lilleby, Investor Relations / Media Relations

jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer. BerGenBio is based in Bergen, Norway with
a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visitwww.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies, and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and subject to the disclosure requirements pursuant to
section 5-12 of the Norwegian Securities Trading Act.

Kilde

[Kaizers]

BerGenBio vurderer strategiske alternativer

[Direkte]

Hvor mye skal aksjen ned de neste dagene?
Vil tro ned til 4 til 5 kr i første omgang.
Nå som hovedstudie feilet

[Freddys]

Bare 50%?

Er ikke normalen 60-70% ned i før handelen?

Ref : Nordic Nanovector - Ultimovacs m.f

[solskimm]

My guess:
Rett ned til cash, deretter cash -50% de neste dagene. Det går mye penger for å legge ned studiene…

[TekBot]

BerGenBio Fourth Quarter Results 2024

Bergen, Norway, February 26, 2025 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharma-ceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, today announced financial results for the quarter
…

Vis børsmeldingen

ended December 31, 2024, and provided a business update.

Highlights, including post period:

BGBC016 1L NSCLC STK11m Study

· Yesterday the company announced its decision to close its BGBC016 study of
bemcentinib in combination with standard of care therapy in first line (1L) non
-squamous Non-Small Cell Lung Cancer (NSCLC) patients with a mutation in the
STK11 gene (STK11m).

Olav Hellebø, Chief Executive Officer of BerGenBio stated, “It is, of course,
disappointing and unexpected that we are now discontinuing the study. I would
like to extend my gratitude to the patients and investigators who participated
in our study for this particularly difficult-to-treat patient group, as well as
to our team members who have worked tirelessly on this effort. We do not believe
these preliminary results are strong enough for the company to obtain additional
funding within the current cash runway to complete the study as originally
designed. The company is now entering a new phase in which strategic
alternatives will be explored, which may include a potential sale, merger, or
other strategic transaction.”

Fourth Quarter and Full-Year 2024 Financial Highlights

· The operating loss for the quarter was NOK 33.5 million and NOK 151.2
million for the full year 2024 (Q4 2023: NOK 43.5 million and full year 2023 NOK
191.8 million)
· Net cash flow for the quarter was negative by NOK 32.9 million and NOK 19.9
for the full year 2024 (Q4 2023: negative by NOK 11.8 million and for the full
year 2023 positive by NOK 2.8 million)
· Cash and cash equivalents amounted to NOK 140.2 million as of 31 December
2024 (NOK 174.8 million 30 September 2024).

Presentation and Financial Report

The Q4 2024 Financial report is attached to this stock exchange announcement and
the report and the Q4 2024 presentation will be available at the Company’s
website: Financial reports - BerGenBio.

Webcast details

BerGenBio’s senior management team will provide a business update today at 10:30
am CET. The presentation will webcast live. To participate in the
webcast (https://channel.royalcast.com/landingpage/hegnarmedia/20250226_5/),
please use the following link:

https://channel.royalcast.com/landingpage/hegnarmedia/20250226_5/ (https://eur03.
safelinks.protection.outlook.com/?url=https%3A%2F%2Fchannel.royalcast.com%2Flandi
ngpage%2Fhegnarmedia%2F20250226_5%2F&data=05%7C02%7Crune.skeie%40bergenbio.com%7C
47aa38284893459da62508dd3ec9f241%7C2b50b422ca6d42af9fc0741b248bb071%7C0%7C0%7C638
735759284905105%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwM
CIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=38A1jsh5UE
CteLfoEd1JYwOKwhq4MlwOmY9DbwDffqg%3D&reserved=0)

A recording of the webcast will be available at www.bergenbio.com in the
Investors/Financial Reports section
(Financial reports - BerGenBio) shortly afterwards.

Contacts

Olav Hellebø, CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer. BerGenBio is based in Bergen, Norway with
a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visitwww.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and subject to the disclosure requirements pursuant to
section 5-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BerGenBio announces advancement of its strategic review

Bergen, Norway, March 17, 2025 - Reference is made to the stock exchange
announcement on 25 February 2025 from BerGenBio ASA (OSE: BGBIO) (the
“Company”), a clinical-stage biopharmaceutical company developing the novel,
…

Vis børsmeldingen

selective AXL kinase inhibitor bemcentinib for serious diseases, in which the
Company amongst other things announced that it will explore strategic
alternatives. The Company today announced that it has engaged Carnegie AS[i], an
entity within the DNB Bank ASA group, as its financial advisor to assist in the
Company’s review of strategic alternatives. The management and Board of
Directors of the Company have together with Carnegie initiated exploration of
potential strategic alternatives that may include, but are not limited to, an
acquisition, merger, business combination, sale of assets, licensing, or other
transactions. The Company does not intend to disclose further developments
unless and until it is determined that further disclosure is appropriate or
legally required.

The Company also announces that it has already implemented significant cost
-containment and cash conservation measures.

Contacts

Olav Hellebø, CEO BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Jan Lilleby,Investor Relations / Media Relations

jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer. BerGenBio is based in Bergen, Norway with
a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visitwww.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies, and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

[i] Part of DNB Bank ASA

Kilde

[Roc]

Fancy pressemelding, men betyr på godt norsk «kroken på døra» for BEM og selskapet ser etter muligheter ala nanovector thor eller zelluna ultimovacs.

Tipper Sarsia som startet herligheten solgte seg ut med fortjeneste, Investinor burde ha klart break even….mens en viss Onkel Mohn i Bergen som spyttet inn 600m kr er nok den som har tapt mest penger.

Jaja…long time coming. Det saktegående togetkræsjet er endelig over. Nå starter oppryddingsjobben.

Var en periode det var ganske heftig diskusjon her. Takk til alle for gode diskusjoner.

[Buffet]

@Roc

Var en periode det var ganske heftig diskusjon her.

Var faktisk en periode det var morsomt å være biotekinvestor også, i 2016-2017 og noen veldig få perioder etter det. Avisoppslag på avisoppslag om de norske selskapene hvor alle var helt i verdenstoppen innen kreftforskning. Utrolig hvilken fadese norsk biotek ble til slutt da Eller kanskje ikke utrolig. Det nåløyet er virkelig trangt å komme igjennom

[hybrid]

Hvordan er stemningen på shareville da, mon tro

[TekBot]

BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in relapsed/refractory Acute Myeloid Leukemia patients

The article identifies promising survival results in relapsed/refractory AML
patients

…

Vis børsmeldingen

warranting further study

Bergen, Norway - 26 March 2025- BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, today announces the publication of a peer-reviewed article
entitled “Bemcentinib as Monotherapy and in Combination with Low-Dose Cytarabine
in Acute Myeloid Leukemia Patients Unfit for Intensive Chemotherapy” in the
journalNature Communications.

This article is accessible here: www.nature.com/articles/s41467-025-58179-6.pdf

The article highlights results in 36 patients treated with a combination of
BerGenBio’s selective oral AXL inhibitor bemcentinib in combination with low
-dose cytarabine(LDAC) chemotherapy. Overall, patients who received the
combination had an overall survival of 7.8 months, substantially longer than
that expected in this difficult-to-treat patient population.

The lead investigator of the study, Professor Sonja Loges, MD, PhD. of the
German Cancer Research Center (DKFZ), Heidelberg, Germany stated, “Following
first line treatment of AML, most patients will relapse, and beyond first line
the prognosis of older patients with relapsed or refractory AML, the population
studied in BGBC003 is particularly poor. With other treatment approaches, the
current overall survival of R/R AML patients is believed to be approximately 2.9
-4 months. The authors of this article believe that the BGBC003 results in this
population warrant further study.”

Olav Hellebo, CEO of BerGenBio commented “Our BGBC003 study evaluated
bemcentinib in relapsed/refractory (R/R) AML patients who have limited effective
treatment options today. The presence of AXL is a poor prognostic factor in
this population and AXL is believed to promote chemotherapy resistance and
decreased antitumor immune response. We believe, as a highly selective AXL
inhibitor, bemcentinib holds promise as a treatment for these patients with
extremely high unmet medical needs.”

Contacts

Olav Hellebo, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Jan Lilleby

jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer. BerGenBio is based in Bergen, Norway with
a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit?www.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde